Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 and Adebrelimab with Chemotherapy in First-Line Advanced Biliary Tract Cancer
NCT06465563Phase 2Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CS1002 in biliary tract cancer (BTC) (3 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Objective Response Rate at 14 months. Started Jul 2024; status: active, not recruiting.
02
Drugs
CS1002
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06465563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465563.